Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1670)	11/11/1998 5:45:00 PM
From: Walter Morton	Respond to of 2742

Steve, I see your point. PRCT's earnings are 250 times less than CIST's (that is after taking into consideration that PRCT only has 3 million shares outstanding). PRCT is trying to develop a product that is geared toward a growing market -- prevention of transplant rejection. Investors understand "prevention of transplant rejection" PRCT has been in talks with other companies about mergers. PRCT has made an acquisition. PRCT work is supported by the government. PRCT is losing over $20 per share yet their stock has gone from $.625 to about $3.50 in one month. So I guess that brings us back to these theories: 1.) There is not a market for CIST's product. 2.) The investors do not understand how to pronounce CIST's product let alone understand what it is capable of doing. 3.) CIST is not using its cash to its advantage. 4.) CIST will not stoop to allowing investor relations firms hype the stock using the pump and dump methods. 5.) If there is a market for CIST's product, will the market grow?